Evidence map›Paper›PMID 38835178›Full record

ReviewDeutsches Arzteblatt international2024

Neuralgic Amyotrophy.

Johannes Fabian Holle, Volker Limmroth, Wolfram Windisch, Maximilian Zimmerman

Abstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Brachial Plexopathies.Current sports medicine reports · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. In Reply.Deutsches Arzteblatt international · 2025
    Article
  12. First-Hand Experience.Deutsches Arzteblatt international · 2025
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Johannes Fabian HolleDepartment of Neurology, Cologne-Merheim, Hospitals of the City of Cologne, Cologne; Cologne-Merheim Lung Clinic, Hospitals of the City of Cologne, Cologne; Health Faculty/Department for Human Medicine, University of Witten/Herdecke.
Volker Limmroth
Wolfram Windisch
Maximilian Zimmerman

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuralgic amyotrophy (NA) is a multifactorial, monophasic neuritis that mainly affects the nerves of the shoulder girdle. It is characterized by very severe pain and by weakness that arises some time after the pain. Its reported incidence is high (100 cases per 100 000 persons per year), but our data suggest that many or most cases are diagnosed late or not at all.

methodsThis review of the epidemiology, pathophysiology, diagnosis, and treatment of NA is based on pertinent publications retrieved by a selective literature search, and on data provided by the scientific institute of AOK, a German statutory health-insurance carrier.

resultsIt is currently thought that the combination of a genetic predisposition, an immunological trigger factor, and mechanical stress on the affected nerve segment(s) is pathophysiologically determinative. The prognosis of untreated NA is poor, with 25% of patients remaining unable to work at three years. The main form of treatment is with corticosteroids that are administered as early as possible. If there is evidence of nerve constriction or torsion, surgery may also help. There have only been six controlled cohort studies on the treatment of NA, and no randomized trials. It is not uncommon for the acute phase to develop into a chronic pain syndrome requiring multidimensional treatment.

conclusionParticularly in view of the high incidence and improved therapeutic options, NA should be included in the differential diagnosis of all patients with suggestive symptoms.

Indexed as

Brachial Plexus NeuritisAdrenal Cortex HormonesDiagnosis, DifferentialEvidence-Based MedicineGermanyHumansIncidenceRisk FactorsTreatment OutcomeAdrenal Cortex Hormones

Identifiers

PMID38835178
PMCPMC11526358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.